Medical News

RSS

NIH-funded study using SphygmoCor published

AtCor Medical the developer and marketer of the SphygmoCor® system which measures central blood pressure and arterial stiffness noninvasively, today announced the publication of a key National Institutes of Health (NIH)-funded study(1) using SphygmoCor in the Journal of the American College of Cardiology (JACC).

2 Nov 2009

Individual, employer mandates prove thorny topics for lawmakers

When President Clinton proposed requiring all Americans to buy insurance in the early 1990s, the non-partisan Congressional Budget Office called it "an unprecedented form of federal action," adding that "[t]he government has never required people to buy any good or service as a condition of lawful residence in the United States," the Los Angeles Times reports.

2 Nov 2009

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Pico-Tesla, The Magneceutical™ Therapy Company, announced today that it has commenced a randomized, double-blind, placebo-controlled Pilot Study of up to 165 persons who have type 2 diabetes, the most common form of diabetes.

2 Nov 2009

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

Blue Cross Blue Shield of Michigan and Oncology Physician Resource announced today the launch of an innovative oncology treatment initiative aimed at enhancing the quality of care for patients with certain types of cancer.

2 Nov 2009

St. David's Medical Center to use FDA cleared CARTO 3 Navigation System for treating cardiac arrhythmia

On Monday, November 2, 2009, Andrea Natale, M.D., F.A.C.C., F.H.R.S., an electrophysiologist and executive medical director of the Texas Cardiac Arrhythmia Institute at St. David's Medical Center, will be the first physician in the United States to perform an ablation procedure to treat a patient with a cardiac arrhythmia, commonly known as an irregular heart rhythm, using the newly FDA-cleared CARTO® 3 Navigation System.

2 Nov 2009

Shortage of Tamiflu in liquid form contributes to dosage errors

Two pediatric patients in Pennsylvania hospitals received overdoses of the drug Tamiflu to treat their flu symptoms because of unawareness among staff as to the concentration of the drug given in an alternative liquid form. Both children were unharmed as a result of the errors, but details of the near misses have been published in a supplementary Pennsylvania Patient Safety Advisory to raise awareness of the issue.

2 Nov 2009

Phase Forward to support FDA's production rollout of the WebSDM tool

Phase Forward, a leading provider of data management solutions for clinical trials and drug safety, today announced a contract award to support the FDA’s production rollout of the company’s WebSDM™ Release 3.0 software, including the Empirica™ Study Clinical Trials Signal Detection system.

2 Nov 2009

Update from Novo Nordisk regarding its share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

From Novo Nordisk 2 Nov 2009

Atrial fibrillation device market will grow by almost 10% through 2013: MRG

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the atrial fibrillation device market will grow by almost 10% through 2013 in the US, Europe, and Japan. MRG's Global Markets for Atrial Fibrillation Devices 2009 report finds that many patients will be treated with electrophysiology technology and related devices as positive clinical results supporting their use emerges.

2 Nov 2009

ISB and Complete Genomics embark on the largest complete human genome disease association study

The Institute for Systems Biology (ISB) and Complete Genomics Inc. announced today that they are embarking on a large-scale human genome sequencing study of Huntington’s disease (HD). ISB has engaged Complete Genomics to sequence 100 genomes, the majority of which will be used to investigate this disease, with samples from affected individuals, family members, and matched controls to study modifiers of disease presentation and progression.

2 Nov 2009

Cooper Norcross Run the Bridge: More than 4,000 runners participate to support school for the disabled

More than a record 4,000 runners and walkers participated in yesterday’s Cooper Norcross Run the Bridge, presented by AmeriHealth New Jersey.

2 Nov 2009

Sanofi Pasteur presents Menactra vaccine safety data at the IDSA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, presented Safety of a Quadrivalent (A,C,Y,W-135) Meningococcal Vaccine When Given to Infants with Other Pediatric Vaccines at the 47th Annual Meeting of the Infectious Diseases Society of America (IDSA) this past weekend.

2 Nov 2009

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

AllOne Health(SM) and Connectyx Technologies Holdings Group, Inc. (Pink Sheets: CTYX) today announced a partnership that will allow consumers to view and manage health information on the Web, via portable USB storage devices and through their mobile phones, with one, secure step. A package including both companies' products will be sold in retail stores across the U.S. in December.

2 Nov 2009

John C. Lincoln Hospital first to use commercially-available LungPoint system

Broncus Technologies, Inc., a medical device company focused on developing minimally-invasive innovations for lung diseases, announced today at the American College of Chest Physicians CHEST 2009 meeting that John C. Lincoln Hospital in Phoenix is the first hospital in the U.S. to use the commercially-available LungPoint system.

2 Nov 2009

McCain's health care adviser is losing his own coverage

Sen. John McCain's top health care adviser in the presidential campaign is about to lose his health care coverage, providing a face to a common dilemma.

2 Nov 2009

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

Dendreon Corporation today announced that it has completed the submission of the amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T), the Company's lead investigational product, to the U.S. Food and Drug Administration (FDA). Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

2 Nov 2009

A look at the odds associated with the influenza virus

What are the odds you will be one of the unlucky ones who gets the flu this year? Book of Odds has launched "Flu Week," a fascinating look at the odds associated with the influenza virus.

2 Nov 2009

New glucose monitoring system from Edwards Lifesciences and Dexcom receives the CE Mark

Edwards Lifesciences Corporation, the leader in the sciences of heart valves and hemodynamic monitoring, and DexCom, Inc., a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems, today announced the receipt of CE Mark for an automatic glucose monitoring system.

2 Nov 2009

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

GTC Biotherapeutics, Inc. announced that LFB Biotechnologies, a wholly owned subsidiary of LFB S.A. (Laboratoire français du Fractionnement et des Biotechnologies S.A., Les Ulis, France) and a strategic shareholder in GTC, has exercised its option to purchase $12.8 million of additional convertible preferred stock under the terms described in the financing agreements approved by GTC shareholders in July 2009. This transaction provides $6.4 million of new cash proceeds to GTC.

2 Nov 2009

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Medical News

NIH-funded study using SphygmoCor published

Individual, employer mandates prove thorny topics for lawmakers

Pico-Tesla commences pilot study of its Resonator system for treating type 2 diabetes patients

Blue Cross Blue Shield of Michigan, OPR launch an innovative oncology treatment initiative

St. David's Medical Center to use FDA cleared CARTO 3 Navigation System for treating cardiac arrhythmia

Shortage of Tamiflu in liquid form contributes to dosage errors

Phase Forward to support FDA's production rollout of the WebSDM tool

Update from Novo Nordisk regarding its share repurchase programme

Atrial fibrillation device market will grow by almost 10% through 2013: MRG

ISB and Complete Genomics embark on the largest complete human genome disease association study

Cooper Norcross Run the Bridge: More than 4,000 runners participate to support school for the disabled

Sanofi Pasteur presents Menactra vaccine safety data at the IDSA

AllOne Health partners with Connectyx Technologies Holdings to provide health information on the Web

John C. Lincoln Hospital first to use commercially-available LungPoint system

McCain's health care adviser is losing his own coverage

Dendreon submits an amended BLA for PROVENGE active cellular immunotherapy

A look at the odds associated with the influenza virus

New glucose monitoring system from Edwards Lifesciences and Dexcom receives the CE Mark

LFB Biotechnologies exercises its option to purchase $12.8 million of stocks in GTC Biotherapeutics

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News